专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 外观设计

USD693925S1 Surgical staple cartridge 有权
标题翻译：手术钉盒
公开(公告)号：USD693925S1
公开(公告)日：2013-11-19
申请号：US29423500
申请日：2012-06-01
申请人： John V. Hunt , Siliang Chen , Peter B. Madson , Zhang Yang , Shan Wan
设计人： John V. Hunt , Siliang Chen , Peter B. Madson , Zhang Yang , Shan Wan

2. 外观设计

USD690809S1 Stapler 有权
公开(公告)号：USD690809S1
公开(公告)日：2013-10-01
申请号：US29423364
申请日：2012-05-31
申请人： John V. Hunt , Siliang Chen , Peter B. Madson , Zhang Yang , Shan Wan
设计人： John V. Hunt , Siliang Chen , Peter B. Madson , Zhang Yang , Shan Wan

3. 发明授权

US09024110B2 Methods for glyco-engineering plant cells for controlled human O-glycosylation 有权
标题翻译：糖酵解植物细胞用于受控人O-糖基化的方法
公开(公告)号：US09024110B2
公开(公告)日：2015-05-05
申请号：US13070248
申请日：2011-03-23
申请人： Zhang Yang , Damian Paul Drew , Emma Adhiambo Arigi , Peter Ulvskov , Steven B. Levery , Eric Bennett , Henrik Clausen , Brent Larsen Petersen
发明人： Zhang Yang , Damian Paul Drew , Emma Adhiambo Arigi , Peter Ulvskov , Steven B. Levery , Eric Bennett , Henrik Clausen , Brent Larsen Petersen
IPC分类号： C12N15/82 , C12N15/12 , C12N15/30 , C12N15/31 , C12N9/10 , C12N9/90 , C12P19/00 , C12P19/44 , A61K38/47 , C12N1/13 , C07K14/47 , C12P21/00
CPC分类号： C12N15/8257 , C07K14/4727 , C12N15/8245 , C12P21/005
摘要： This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon α2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation. Introduction of O-glycosylation into plant cells requires i) that wild-type plant cells do not modify the target peptide substrates and ii) that the appropriate enzymes and substrates are introduced into of plant cells such that O-glycosylation in the secretory pathway proceed and the glycosylated peptide substrates are preferentially exported to the exterior of the cell or accumulated in the cell. In this invention i) the integrity of transiently and stably expressed ‘mucin’ type target peptides in plants cells has been determined and ii) mucin-type O-glycosylation has been established in plants by transient and stable introduction of a Pseudomonas aeruginosa C4-epimerase, the human polypeptide GalNAc-transferases T2 and T4 (GalNAc-T2 and T4) and various human target peptides or proteins. In the present invention GalNAc-T2 and -T4 have been used to produce a Tn cancer glycoform of MUC1.
摘要翻译：本发明公开了在植物中重组生物活性糖蛋白和癌特异性疫苗重组生产的新平台的开发。植物和植物细胞培养物相对于人粘蛋白型蛋白O-糖基化已被人源化。已经开发了一组用于生产具有设计的人O-糖基化的重组糖蛋白的植物细胞工厂，包括改进的癌症疫苗候选物。该平台为i）生产基本上无限量的O-糖基化的人类糖蛋白治疗剂例如人干扰素α2B和podoplanin的基础，以及ii）用于在治疗价值的糖蛋白上进一步工程化另外的癌症特异性O-聚糖。目前，哺乳动物细胞是人O-糖基化所必需的，但由于它们不进行人类O-糖基化，植物提供了独特的用于工程化O-糖基化的细胞平台。将O-糖基化引入到植物细胞中需要i）野生型植物细胞不修饰靶肽底物，和ii）将合适的酶和底物引入植物细胞，使分泌途径中的O-糖基化进行，糖基化肽底物优选地输出到细胞的外部或者积聚在细胞中。在本发明中，i）已经确定了植物细胞中瞬时稳定表达的“粘蛋白”型靶肽的完整性，并且ii）通过暂时稳定地引入铜绿假单胞菌C4差向异构酶，在植物中建立了粘蛋白型O-糖基化，人多肽GalNAc-转移酶T2和T4（GalNAc-T2和T4）和各种人靶肽或蛋白质。在本发明中，已经使用GalNAc-T2和-T4来产生MUC1的Tn癌糖蛋白。

4. 发明申请

US20110237782A1 METHODS FOR GLYCO-ENGINEERING PLANT CELLS FOR CONTROLLED HUMAN O-GLYCOSYLATION 有权
标题翻译：用于控制人类O-糖蛋白化的植物工程细胞的方法
公开(公告)号：US20110237782A1
公开(公告)日：2011-09-29
申请号：US13070248
申请日：2011-03-23
申请人： Zhang Yang , Damian Paul Drew , Emma Adhiambo Arigi , Peter Ulvskov , Steven B. Levery , Eric Paul Bennett , Henrik Clausen , Brent Larsen Petersen
发明人： Zhang Yang , Damian Paul Drew , Emma Adhiambo Arigi , Peter Ulvskov , Steven B. Levery , Eric Paul Bennett , Henrik Clausen , Brent Larsen Petersen
IPC分类号： C07K14/00 , C12N15/82 , C12P21/00
CPC分类号： C12N15/8257 , C07K14/4727 , C12N15/8245 , C12P21/005
摘要： This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon α2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation. Introduction of O-glycosylation into plant cells requires i) that wild-type plant cells do not modify the target peptide substrates and ii) that the appropriate enzymes and substrates are introduced into of plant cells such that O-glycosylation in the secretory pathway proceed and the glycosylated peptide substrates are preferentially exported to the exterior of the cell or accumulated in the cell. In this invention i) the integrity of transiently and stably expressed ‘mucin’ type target peptides in plants cells has been determined and ii) mucin-type O-glycosylation has been established in plants by transient and stable introduction of a Pseudomonas aeruginosa C4-epimerase, the human polypeptide GalNAc-transferases T2 and T4 (GalNAc-T2 and T4) and various human target peptides or proteins. In the present invention GalNAc-T2 and -T4 have been used to produce a Tn cancer glycoform of MUC1.
摘要翻译：本发明公开了在植物中重组生物活性糖蛋白和癌特异性疫苗重组生产的新平台的开发。植物和植物细胞培养物相对于人粘蛋白型蛋白O-糖基化已被人源化。已经开发了一组用于生产具有设计的人O-糖基化的重组糖蛋白的植物细胞工厂，包括改进的癌症疫苗候选物。该平台为i）生产基本上无限量的O-糖基化的人类糖蛋白治疗剂例如人干扰素α2B和podoplanin的基础，以及ii）用于在治疗价值的糖蛋白上进一步工程化另外的癌症特异性O-聚糖。目前，哺乳动物细胞是人O-糖基化所必需的，但由于它们不进行人类O-糖基化，植物提供了独特的用于工程化O-糖基化的细胞平台。将O-糖基化引入到植物细胞中需要i）野生型植物细胞不修饰靶肽底物，和ii）将合适的酶和底物引入植物细胞，使分泌途径中的O-糖基化进行，糖基化肽底物优选地输出到细胞的外部或者积聚在细胞中。在本发明中，i）已经确定了植物细胞中瞬时稳定表达的“粘蛋白”型靶肽的完整性，并且ii）通过暂时稳定地引入铜绿假单胞菌C4差向异构酶，在植物中建立了粘蛋白型O-糖基化，人多肽GalNAc-转移酶T2和T4（GalNAc-T2和T4）和各种人靶肽或蛋白质。在本发明中，已经使用GalNAc-T2和-T4来产生MUC1的Tn癌糖蛋白。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式